ASLAN Pharmaceuticals Limited (ASLN)

NASDAQ: ASLN · IEX Real-Time Price · USD

0.281

-0.019 (-6.33%)

At close: Jul 2, 2024, 4:00 PM

0.284

+0.003 (1.03%)

After-hours: Jul 2, 2024, 7:33 PM EDT

ASLAN Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018 - 2016
Market Capitalization	6	9	25	78	70	65	Upgrade
Market Cap Growth	-77.15%	-64.23%	-67.82%	12.23%	6.86%	-46.09%	Upgrade
Enterprise Value	15	15	6	19	75	62	Upgrade
PE Ratio	-	-0.20	-0.49	-2.47	-4.10	-1.38	Upgrade
PS Ratio	0.53	0.75	-	-	-	21.69	Upgrade
PB Ratio	-0.59	-0.68	3.00	1.36	-6.65	-38.79	Upgrade
P/FCF Ratio	-	-0.21	-0.70	-2.29	-4.62	-2.55	Upgrade
P/OCF Ratio	-	-0.21	-0.70	-2.30	-4.62	-2.55	Upgrade
EV/Sales Ratio	1.22	1.21	-	-	-	20.50	Upgrade
EV/EBITDA Ratio	-	-0.37	-0.13	-0.65	-4.83	-1.36	Upgrade
EV/EBIT Ratio	-0.61	-0.37	-0.12	-0.64	-4.74	-1.34	Upgrade
EV/FCF Ratio	-	-0.34	-0.16	-0.56	-4.95	-2.41	Upgrade
Debt / Equity Ratio	-1.48	-2.02	4.51	0.55	-1.87	-11.12	Upgrade
Debt / EBITDA Ratio	-	-0.68	-0.80	-1.06	-1.27	-0.41	Upgrade
Debt / FCF Ratio	-	-0.62	-1.05	-0.92	-1.30	-0.73	Upgrade
Quick Ratio	0.94	1.62	2.46	14.18	1.36	4.12	Upgrade
Current Ratio	1.05	1.84	2.63	14.75	1.46	4.14	Upgrade
Asset Turnover	0.33	0.26	0	0	0	0.08	Upgrade
Interest Coverage	-7.90	-9.18	-12.95	-15.98	-12.61	-50.75	Upgrade
Return on Equity (ROE)	543.80%	-8453.60%	-190.00%	-44.90%	188.50%	-325.30%	Upgrade
Return on Assets (ROA)	-96.30%	-95.70%	-67.30%	-31.80%	-108.90%	-123.50%	Upgrade
Return on Capital (ROIC)	-401.40%	-323.05%	-103.92%	-38.21%	-181.75%	-268.56%	Upgrade
Earnings Yield	-550.90%	-492.35%	-204.64%	-40.49%	-24.41%	-72.34%	Upgrade
FCF Yield	-482.45%	-143.34%	-43.63%	-21.65%	-39.20%	Upgrade
Buyback Yield / Dilution	-25.91%	-17.93%	-7.07%	-69.43%	-18.37%	-8.45%	Upgrade
Total Shareholder Return	-25.91%	-17.93%	-7.07%	-69.43%	-18.37%	-8.45%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).